Editorial
Standards

This page explains how we research and write the content on GlobalGLP1: what sources we trust, how we handle medical claims, when we update articles, and what conflicts of interest we disclose. If we cite a number or make a claim, we want you to be able to trace it.

Directory data refreshed: March 2026.

When we write about medications, weight loss outcomes, side effects, dosing, or insurance coverage, we cite sources in this order of priority:

1. FDA prescribing information. The official drug label is the primary source for indications, dosing, contraindications, warnings, and approved use cases. Labels are linked directly from medication pages where applicable.

2. Peer-reviewed clinical trials. We cite published trial data from journals like the New England Journal of Medicine (NEJM), JAMA, The Lancet, and Diabetes Care for efficacy, safety, and outcome claims. We name the trial (STEP, SURMOUNT, SCALE, SUSTAIN, etc.) and link the publication where possible.

3. Manufacturer medical information. Novo Nordisk and Eli Lilly publish patient-facing dosing schedules, savings programs, and prescribing data. We use this for pricing and program details, clearly attributed.

4. Federal health agencies. CMS (Medicare/Medicaid), CDC, and NIH for coverage policy, public health statistics, and clinical guidance.

5. Reputable health journalism. STAT, Reuters Health, AP, NPR Health, and major medical journals' news desks, used as secondary references and never as the sole source for a medical claim.

Content on GlobalGLP1 is written and reviewed in house, led by our founder, who has research and writing experience in digital health publishing. We are a small operation, not a newsroom. Nobody working on this site is a licensed physician or other medical professional. We do not provide medical advice, diagnoses, or treatment recommendations. Everything we publish is informational, sourced from the primary references above, and should be discussed with a qualified clinician before acting on it.

Every medication page, insurance guide, and blog post is reviewed against its primary sources before publication. Articles are updated when the FDA approves a new indication, when a major trial publishes new data, when a manufacturer changes pricing or savings programs, or when a reader flags an error we verify.

Medication pages (Wegovy, Ozempic, Mounjaro, Zepbound, semaglutide, tirzepatide, liraglutide) were last checked against FDA labelling and the manufacturers’ own published information in August 2026. They are re-checked when the FDA approves a new indication, changes a label, issues a safety communication, or when a major trial publishes outcome data.

Insurance pages (Aetna, BCBS, Cigna, UHC, Medicare, Medicaid, state-by-state coverage) were last checked against CMS, the eCFR and KFF in August 2026. Each sourced block on those pages also carries its own “checked” date beside the claim it supports. They are re-checked when CMS publishes new coverage policy or a major payer announces a formulary change.

Clinic listings are refreshed on a rolling basis from Google Business data, the clinic’s own website, and owner-submitted updates. Each listing shows the month its data was sourced, and whether that came from public sources or from the owner.

Blog posts and guides are re-read when reader feedback or new published research warrants it, and were last reviewed as a whole in August 2026. We do not promise a fixed cadence for them, because we have not been keeping one.

We use software to gather public data at scale (Google Business profiles, clinic websites, regulatory databases) and to draft content. A human checks medical claims against the primary sources before publication, and again in periodic reviews of whole sections.

That process is not perfect and we would rather show you the seam than pretend there is not one. We have found published errors after the fact, including drug prices that had been superseded and one page whose advice about birth control did not match the medication’s FDA label. Both were found in a review, corrected, and the review date on the page moved. Every medication page now lists the exact labels and trials behind its numbers so you can check any of them yourself.

We do not publish medical content that has had no source review at all.

We do not use AI to generate fake reviews, fake credentials, fake testimonials, or fabricated medical statistics. We do not publish content under invented author names. Where a page carries the byline "GlobalGLP1 Editorial Team", that is a house byline rather than a person we made up.

How we make money: Optional premium listings for clinics ($99 per month) that give them enhanced visibility in the default sort order on city, state, and search results pages. Premium listings are always labeled "Sponsored."

Editorial content is independent of advertising. Premium status does not affect medication page content, insurance page content, blog post coverage, Google ratings, or ranking on editorial pages like "Top Rated," "Best Telehealth," "Best Semaglutide," and "Best Tirzepatide." Editorial ranking pages explicitly exclude paid placement boosts. See our full ranking methodology.

What we do not accept: Payment for editorial coverage. Affiliate commissions on clinic bookings or medication referrals. Payment from pharmaceutical manufacturers. Payment for blog posts, sponsored articles, or guest content. We do not sell patient contact information or user data.

Ownership: GlobalGLP1 is independently owned and operated. We are not affiliated with any pharmaceutical manufacturer, telehealth platform, or clinic network. Our mailing address is in Miami, Florida.

We make mistakes. When you find one, our corrections policy explains exactly how to report it and how fast you should expect a response (2 business days for factual errors, 5 business days for listing details).

When we correct something substantive we fix the page itself and move the review date shown on it, so the date tells you when the content was last checked rather than when it was first written. We do not currently publish a per-article correction log, and we would rather say so than claim one we do not keep.

We do not quietly delete a page to make an error disappear. Retired pages redirect to whatever now covers the subject.